ArticlePigment cell & melanoma research2015

The broad-spectrum receptor tyrosine kinase inhibitor dovitinib suppresses growth of BRAF-mutant melanoma cells in combination with other signaling pathway inhibitors.

Casey G Langdon et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.